Can-Fite BioPharma (NYSE:CANF) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report sent to investors on Monday. The brokerage issued a sell rating on the stock.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Can-Fite BioPharma in a report on Tuesday, March 18th.

Can-Fite BioPharma Trading Up 0.1 %

Shares of CANF opened at $1.48 on Monday. The firm’s fifty day simple moving average is $1.58 and its two-hundred day simple moving average is $1.83. Can-Fite BioPharma has a 12 month low of $1.29 and a 12 month high of $4.69. The stock has a market capitalization of $5.24 million, a P/E ratio of -0.83 and a beta of 1.12.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers grew its stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 26,880 shares of the company’s stock after purchasing an additional 9,935 shares during the period. Rhumbline Advisers owned about 0.76% of Can-Fite BioPharma worth $44,000 as of its most recent filing with the SEC. Institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.